Q-omics provides the consensus-scored GPR22 profile across patient tissues and cancer cell-line models. GPR22 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GPR22 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, GPR22 RNA expression shows 13,826 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight ACC, KIRC, and PCPG as cancer lineages where GPR22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR22 survival associations across molecular data types. GPR22 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR22 RNA expression–survival associations across cancer types. High GPR22 expression shows unfavorable associations in ACC, KIRC, THCA, DLBC and UVM, but favorable associations in UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GPR22 RNA expression.
This table summarizes GPR22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR22 shows lower tumor expression in KIRC, KIRP, THCA, KICH, STAD and UCEC. The KIRC box plot shows higher GPR22 RNA expression in normal versus tumor tissue (log2 FC = −0.439, t-test p < 0.001).
This table shows molecular features associated with GPR22 in patient tissues and cancer cell lines. In patient samples, GPR22 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
